Dehydrostobadine

Dehydrostobadine

SCHEMBL167500

Cc1ccc2[nH]c3c(c2c1)CN(C)CC3

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.97
SIRT2 Q8IXJ6 1/20 0.74
ACHE P22303 4/20 0.69
GRIN1 Q05586 3/20 0.69
GRIN2A Q12879 3/20 0.69
GRIN2D O15399 2/20 0.69
GRIN3B O60391 2/20 0.69
GRIN2B Q13224 2/20 0.69
GRIN2C Q14957 2/20 0.69
GRIN3A Q8TCU5 2/20 0.69
ALOX15 P16050 2/20 0.67
HSD17B10 Q99714 2/20 0.67
USP2 O75604 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2D6 P10635 1/20 0.67
CYP2C9 P11712 1/20 0.67
CHRNA7 P36544 1/20 0.66
BAZ2B Q9UIF8 1/20 0.65
HTR6 P50406 3/20 0.61
POLB P06746 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydrostobadine SCHEMBL29468212 1.00 L3MBTL1 (0.97) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL3715610 0.98 L3MBTL1 (1.00) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL2837548 0.98 L3MBTL1 (1.00) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL10127681 0.91 L3MBTL1 (0.82) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL13320178 0.90 L3MBTL1 (0.80) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL3238110 0.89 L3MBTL1 (0.78) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL1120507 0.88 L3MBTL1 (0.76) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL15977201 0.88 L3MBTL1 (0.76) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL12868029 0.86 L3MBTL1 (0.73) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL3024458 0.84 L3MBTL1 (0.70) L3MBTL1SIRT2ACHEGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303577-A1 TEMOZOLOMIDE ANALOGS AND METHODS OF USE ST. JOHN'S CANCER INSTITUTE (US) 2023-09-28 US claimed
EP-2420235-A1 Methods and combination therapies for treating alzheimer's disease Medivation Neurology, Inc. (US) 2012-02-22 EP claimed
US-20100152108-A1 METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE MEDIVATION NEUROLOGY, INC. (US) 2010-06-17 US claimed
US-20100152225-A1 HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME MEDIVATION NEUROLOGY, INC. 2010-06-17 US claimed
US-20100099700-A1 HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) MEDIVATION NEUROLOGY, INC. 2010-04-22 US claimed
WO-2009111540-A1 METHODS FOR PREPARING PYRIDYLETHYL-SUBSTITUTED CARBOLINES MEDIVATION NEUROLOGY, INC. (US) 2009-09-11 WO claimed
EP-2086538-A2 COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE USING I.A. DIMEBON AND DOLEPEZIL Medivation Neurology, Inc. (US) 2009-08-12 EP claimed
EP-2063892-A2 METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) Medivation Neurology, Inc. (US) 2009-06-03 EP claimed
WO-2009039420-A9 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES MEDIVATION NEUROLOGY INC (US) 2009-05-07 WO claimed
WO-2009039420-A1 METHODS AND COMPOSITIONS FOR TREATING NEURONAL DEATH MEDIATED OCULAR DISEASES MEDIVATION NEUROLOGY, INC. (US) 2009-03-26 WO claimed
WO-2008036410-A2 METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) MEDIVATION NEUROLOGY, INC. (US) 2008-03-27 WO claimed
US-20070225316-A1 Methods and compositions for treating schizophrenia MEDIVATION, INC. 2007-09-27 US claimed
WO-2007087425-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA MEDIVATION NEUROLOGY,INC. (US) 2007-08-02 WO claimed
US-20070179174-A1 Methods and compositions for slowing aging MEDIVATION, INC. 2007-08-02 US claimed
US-20070117835-A1 Methods and compositions for treating Huntington's disease MEDIVATION NEUROLOGY, INC. 2007-05-24 US claimed
US-20070117834-A1 Methods and compositions for treating Huntington's disease MEDIVATION NEUROLOGY, INC. 2007-05-24 US claimed
WO-2007041697-A2 HYDROGENATED PYRIDO-INDOLE COMPOUNDS FOR THE TREATMENT OF HUNTINGTON ' S DISEASE MEDIVATION, INC. (GB) 2007-04-12 WO claimed
EP-1692131-A2 METHODS AND COMPOSITIONS FOR SLOWING AGING MEDIVATION, INC. (US) 2006-08-23 EP claimed
WO-2005055951-A2 METHODS AND COMPOSITIONS FOR SLOWING AGING MEDIVATION, INC. (US) 2005-06-23 WO claimed
EP-0876818-B1 AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS SELENA PHARMACEUTICALS INC (US) 2002-12-18 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152108-A1 METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE PSEN2, APP, PSEN1 L3MBTL1 4152/4885SIRT2 78/4885ACHE 12/4885
US-20070225316-A1 Methods and compositions for treating schizophrenia SLC6A3, DBH, GRIN3B L3MBTL1 4439/4885SIRT2 575/4885ACHE 393/4885
US-20070179174-A1 Methods and compositions for slowing aging PRDX5, HMOX1, SHMT2 L3MBTL1 1438/4885SIRT2 54/4885ACHE 398/4885
US-20070117835-A1 Methods and compositions for treating Huntington's disease HTT, HYPK, HTR6 L3MBTL1 4123/4885SIRT2 284/4885ACHE 171/4885
US-20230303577-A1 TEMOZOLOMIDE ANALOGS AND METHODS OF USE MGMT, TOP2B, IDH3B L3MBTL1 2328/4885SIRT2 284/4885ACHE 2967/4885
US-20100152225-A1 HYDROGENATED PYRIDO [4,3-B] INDOLES SUCH AS DIMEBON FOR TREATING CANINE COGNITIVE DYSFUNCTION SYNDROME HPD, KYNU, IDO1 L3MBTL1 3532/4885SIRT2 319/4885ACHE 1153/4885
US-20100099700-A1 HYDROGENATED PYRIDO (4,3-B) INDOLES FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) HTT, NLN, SMN1; SMN2 L3MBTL1 321/4885SIRT2 286/4885ACHE 164/4885
US-20070117834-A1 Methods and compositions for treating Huntington's disease HTT, HYPK, HTR6 L3MBTL1 4123/4885SIRT2 284/4885ACHE 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.